Hims & Hers CEO Defends Data Practices, Sees GLP-1 Prices Falling to $40-$50
Updated
Updated · CNBC · Aug 18
Hims & Hers CEO Defends Data Practices, Sees GLP-1 Prices Falling to $40-$50
1 articles · Updated · CNBC · Aug 18
Summary
Andrew Dudum said the FTC lawsuit reflects a misunderstanding of Hims & Hers' digital healthcare model, after regulators in July accused the company of sharing health data, charging before consultations and obstructing cancellations.
The CEO said Hims & Hers had worked with the FTC for years and argued the company’s business is designed to expand access to care rather than exploit patients.
On weight-loss drugs, Dudum defended the company’s earlier sale of compounded GLP-1s during shortages and said that pressure helped push the market toward lower prices.
Hims & Hers shifted to branded GLP-1s after Novo Nordisk dropped a patent suit in March, and Dudum said cash-pay prices could fall from about $150-$200 a month to $40-$50.
Dudum also said the company is investing to become 'AI native,' moving away from third-party tools to build in-house systems around its proprietary healthcare data.